CardioBrief has learned from multiple sources that Sanjay Kaul will not be a member of the FDA advisory panel on Tuesday’s hearing to evaluate prasugrel. Kaul has been a sharp critic of recent drug trials, and has raised public concerns about prasugrel and other cardiovascular agents in recent years. Kaul’s name appeared on the FDA roster posted on the FDA website last Friday. Although his name still appeared on the document at the time of this posting, Kaul was removed late last week from the committee for having an intellectual conflict of interest, though it is unclear exactly what this means or what it implies. Certainly the FDA had to have known that Kaul was an outspoken critic– just google “Kaul and prasugrel” to see what I mean. So this raises the question: what prompted this last minute dramatic move on the part of the FDA?
The Uninvited: Sanjay Kaul removed from prasugrel’s FDA advisory panel
February 2, 2009 by 5 Comments
Trackbacks
-
[…] first reported here previously, less than 48 hours before the advisory committee hearing new member Sanjay Kaul was […]
-
[…] Sanjay Kaul’s absence from the prasugrel advisory committee meeting (click to see our initial story that first reported his absence and our subsequent editorial about some serious questions raised by the advisory committee […]
-
[…] was removed without explanation from the prasugrel (Efient, Lilly) advisory panel (as recounted here, here, here, and here), provoking considerable controversy and two congressional […]
[…] There’s another absence that’s also raising questions. Sanjay Kaul, a cardiologist at Cedars -Sinai Heart Institute and a voting member of the Cardio Advisory Committee, was removed from the panel last week over “intellectual conflict of interest,” according to the blog Cardio Brief. […]